RYTVELA is a derivative of the peptide antagonist rytvela, targeting interleukin-1 receptor 1 (IL-1R1), and is comprised entirely of L-amino acids.

H-Val-Ala-OH (Valyl-alanine) is a dipeptide formed from L-Valine and L-Alanine residues. It has a role as a metabolite. H-Val-Ala-OH is a dipeptide formed from L-Valine and L-Alanine residues.

H-Ile-Lys-Val-Ala-Val-OH, a significant active site within laminin-1, enhances cell adhesion, neurite outgrowth, and tumor growth. It also encourages the growth and proliferation of BMMSC populations through the activation of MAPK/ERK1/2 and PI3K/Akt signaling pathways [1] [2].